Trial · NCT02475681
Results by group13
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 13 of 13
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Progression-free Survival by IRC (Independent Review Committee) Assessment in Arm A Compared to Arm B | Arm A: Obinutuzumab in Combination With Chlorambucil | 22.6 | 95% Confidence Interval 20.2 to 27.8 | Months | |
| Progression-free Survival by IRC (Independent Review Committee) Assessment in Arm A Compared to Arm B | Arm B: Acalabrutinib in Combination With Obinutuzumab | NA | 95% Confidence Interval NA to NA | Months | |
| Progression-free Survival by IRC Assessment Arm A Versus Arm C | Arm A: Obinutuzumab in Combination With Chlorambucil | 22.6 | 95% Confidence Interval 20.2 to 27.6 | Months | |
| Progression-free Survival by IRC Assessment Arm A Versus Arm C | Arm C: Acalabrutinib Monotherapy | NA | 95% Confidence Interval 34.2 to NA | Months | |
| IRC-assessed Objective Response Rate (ORR) in Arm A Versus Arm B and Arm A Versus Arm C | Arm A: Obinutuzumab in Combination With Chlorambucil | 78.5 | 95% Confidence Interval 71.9 to 83.9 | percentage of participants | |
| IRC-assessed Objective Response Rate (ORR) in Arm A Versus Arm B and Arm A Versus Arm C | Arm B: Acalabrutinib in Combination With Obinutuzumab | 93.9 | 95% Confidence Interval 89.3 to 96.5 | percentage of participants | |
| IRC-assessed Objective Response Rate (ORR) in Arm A Versus Arm B and Arm A Versus Arm C | Arm C: Acalabrutinib Monotherapy | 85.5 | 95% Confidence Interval 79.6 to 89.9 | percentage of participants | |
| Time to Next Treatment (TTNT) in Arm A Versus Arm B and Arm A Versus Arm C | Arm A: Obinutuzumab in Combination With Chlorambucil | NA | 95% Confidence Interval 28.9 to NA | Months | |
| Time to Next Treatment (TTNT) in Arm A Versus Arm B and Arm A Versus Arm C | Arm B: Acalabrutinib in Combination With Obinutuzumab | NA | 95% Confidence Interval NA to NA | Months | |
| Time to Next Treatment (TTNT) in Arm A Versus Arm B and Arm A Versus Arm C | Arm C: Acalabrutinib Monotherapy | NA | 95% Confidence Interval NA to NA | Months | |
| Overall Survival (OS) in Arm A Versus Arm B and Arm A Versus Arm C | Arm A: Obinutuzumab in Combination With Chlorambucil | NA | 95% Confidence Interval NA to NA | Months | |
| Overall Survival (OS) in Arm A Versus Arm B and Arm A Versus Arm C | Arm B: Acalabrutinib in Combination With Obinutuzumab | NA | 95% Confidence Interval NA to NA | Months | |
| Overall Survival (OS) in Arm A Versus Arm B and Arm A Versus Arm C | Arm C: Acalabrutinib Monotherapy | NA | 95% Confidence Interval NA to NA | Months |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT02475681/results